PFIZER INC Research and Development in Process
PFIZER INC (PFE) reported Research and Development in Process of $125.00 million for the 12-month period ending 2010-12-31, per its 10-K filed 2012-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2012-02-28
- PFIZER INC research and development in process for the quarter ending 2010-12-31 was $51.00M, a 6.25% increase year-over-year.
- PFIZER INC research and development in process for the quarter ending 2010-10-03 was $0.00.
- PFIZER INC research and development in process for the quarter ending 2010-07-04 was $0.00, a 100.00% decline year-over-year.
- PFIZER INC research and development in process for the quarter ending 2010-04-04 was $74.00M.
- PFIZER INC research and development in process for fiscal 2010 was $125.00M, a 83.82% increase from fiscal 2009.
- PFIZER INC research and development in process for fiscal 2009 was $68.00M, a 89.26% decline from fiscal 2008.
- PFIZER INC research and development in process for fiscal 2008 was $633.00M, a 123.67% increase from fiscal 2007.
- PFIZER INC research and development in process for fiscal 2007 was $283.00M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2010-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $51.00M derived: sum of 2 quarters · filed 2012-02-28 | $51.00M derived: sum of 3 quarters · filed 2012-02-28 | $125.00M 10-K · filed 2012-02-28 |
| 2010-10-03 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $0.00 derived: sum of 2 quarters · filed 2011-11-10 | $74.00M 10-Q · filed 2011-11-10 | $122.00M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-07-04 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-12 | $74.00M 10-Q · filed 2011-08-11 | $122.00M derived: sum of 3 quarters · filed 2012-02-28 | $122.00M derived: sum of 4 quarters · filed 2012-02-28 |
| 2010-04-04 | $74.00M 10-Q · filed 2011-05-12 | $122.00M derived: sum of 2 quarters · filed 2012-02-28 | $122.00M derived: sum of 3 quarters · filed 2012-02-28 | $142.00M derived: sum of 4 quarters · filed 2012-02-28 |
| 2009-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $48.00M derived: sum of 2 quarters · filed 2012-02-28 | $68.00M derived: sum of 3 quarters · filed 2012-02-28 | $68.00M 10-K · filed 2012-02-28 |
| 2009-09-27 | $0.00 10-Q · filed 2009-11-05 | $20.00M derived: sum of 2 quarters · filed 2010-08-12 | $20.00M 10-Q · filed 2010-11-12 | |
| 2009-06-28 | $20.00M 10-Q · filed 2010-08-12 | $20.00M 10-Q · filed 2010-08-12 | ||
| 2008-12-31 | $66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $79.00M derived: sum of 2 quarters · filed 2011-02-28 | $235.00M derived: sum of 3 quarters · filed 2011-02-28 | $633.00M 10-K · filed 2011-02-28 |
| 2008-09-28 | $13.00M 10-Q · filed 2009-11-05 | $169.00M derived: sum of 2 quarters · filed 2009-11-05 | $567.00M 10-Q · filed 2009-11-05 | |
| 2008-06-29 | $156.00M 10-Q · filed 2009-08-06 | $554.00M 10-Q · filed 2009-08-06 | ||
| 2007-12-31 | $283.00M 10-K · filed 2010-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |